Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L DeMets

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Heart Rhythm|March 22, 2017
Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trialMatthew M Kalscheur, Leslie A Saxon, Byron K Lee, et al.
Family Medicine and Community Health|December 25, 2021
Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not ageKyungmann Kim, Charles H Hennekens, Lisa Martinez, et al.
Therapeutic Innovation & Regulatory Science|February 11, 2022
Ivermectin in COVID-19: The Case for a Moratorium on PrescriptionsAndreea Molnar, Stephanie Lau, Maja Berges, et al.
Contemporary Clinical Trials|March 18, 2022
The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE studyZhen Huang, Frank W Rockhold, W Schuyler Jones, et al.
European Journal of Heart Failure|March 22, 2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)John J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Journal of Cardiac Failure|February 11, 2005
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot studyMilton Packer, John McMurray, Barry M Massie, et al.
Circulation|October 23, 2002
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) studyMilton Packer, Michael B Fowler, Ellen B Roecker, et al.
JACC. Heart Failure|March 26, 2024
Training the Next Generation of Data Monitoring Committee Members: An Initiative of the Heart Failure CollaboratoryThomas R Fleming, Janet Wittes, Mona Fiuzat, et al.
Diabetes Care|October 21, 2020
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering TherapyKieran F Docherty, Pardeep S Jhund, Olof Bengtsson, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Heart Rhythm|March 22, 2017
Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trialMatthew M Kalscheur, Leslie A Saxon, Byron K Lee, et al.
Family Medicine and Community Health|December 25, 2021
Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit-risk ratio, not ageKyungmann Kim, Charles H Hennekens, Lisa Martinez, et al.
Therapeutic Innovation & Regulatory Science|February 11, 2022
Ivermectin in COVID-19: The Case for a Moratorium on PrescriptionsAndreea Molnar, Stephanie Lau, Maja Berges, et al.
Contemporary Clinical Trials|March 18, 2022
The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE studyZhen Huang, Frank W Rockhold, W Schuyler Jones, et al.
European Journal of Heart Failure|March 22, 2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)John J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Journal of Cardiac Failure|February 11, 2005
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot studyMilton Packer, John McMurray, Barry M Massie, et al.
Circulation|October 23, 2002
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) studyMilton Packer, Michael B Fowler, Ellen B Roecker, et al.
JACC. Heart Failure|March 26, 2024
Training the Next Generation of Data Monitoring Committee Members: An Initiative of the Heart Failure CollaboratoryThomas R Fleming, Janet Wittes, Mona Fiuzat, et al.
Diabetes Care|October 21, 2020
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering TherapyKieran F Docherty, Pardeep S Jhund, Olof Bengtsson, et al.
Pageof 10